drugset / Trial / NCT01305837

Cyclic Oral Methylprednisolone Trial in Multiple Sclerosis

NCT01305837

Phase 2 Completed 30 enrolled Rigshospitalet, Denmark
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to determine whether cyclic oral methylprednisolone once every month has an effect on the intrathecal inflammation in patients suffering from progressive multiple sclerosis.

Timeline

Start
2011-04
Primary completion
2013-07
Completion
2013-07

Drugs

EvaluationDrugModalityDoseRoute
Subject Methylprednisolone Other / unclassified 500 mg Oral